NervGen Pharma

1. NVG-291 Ph1 interim2026NVG-291 Ph1 interim, 2026, notable
2. NVG-291 Ph3 startMid-2026NVG-291 Ph3 start, Mid-2026, routine
3. NVG-291 filing3Q 2026NVG-291 filing, 3Q 2026, notable
4. NervGen financingJan 1, 2027NervGen financing, Jan 1, 2027, routine
5. NGEN corporate trial startJan 1, 2027NGEN corporate trial start, Jan 1, 2027, routine
6. RESTORE Phase 3 corporate update2H 2027RESTORE Phase 3 corporate update, 2H 2027, routine
7. NVG-291 Ph3 topline1H 2028NVG-291 Ph3 topline, 1H 2028, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.